RE:Trialsit makes sense that moving to a registration enabling clinical trial would certainly involve roche or one of the other bp's.
if that is the case, the lawyers on both sides are working as we speak.
neither party would want a stain from a failure of trial design and there would need to be an agreement which allocated costs and expenses as well as agreement on which surrogate endpoints to use, what biomarkers would be most relevant, what product(s) to combine with pela, when/how data would be shared,etc.
expect more quiet time and a lot of speculation before we hear anything definitive. stock price movements as well as volume traded might just have to serve as a proxy for those not directly involved to gauge what might be happening.
days, weeks, months? maybe bringing on a new "head" for the san diego office would be telling.